Novartis AG - Company Profile

Powered by

All the sales intelligence you need on Novartis AG in one solution.

$395 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Novartis AG fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Novartis AG.

Back to companies

Novartis AG: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

View more

Novartis AG (Novartis) is a pharmaceutical company that is engaged in the research, development, manufacturing, distribution, marketing, and sale of innovative medicines. It offers a range of products in therapeutic areas such as cardiovascular, renal and metabolic, immunology, ophthalmology, respiratory, global health, neuroscience, and oncology. The company offers its products to pharmacists, private health systems, government agencies, physicians, hospitals, insurance groups, managed care providers, pharmacy benefit managers, and government-supported healthcare systems through brands such as Entresto, Cosentyx, Kesimpta, Kisqali, and Tasigna, among others, globally. It operates manufacturing facilities in the US, Switzerland, Austria, Slovenia, China, France, and Italy. Novartis is headquartered in Basel, Switzerland.

 Gain a 360-degree view of Novartis AG and make more informed decisions for your business Gain a 360-degree view of Novartis AG and make more informed decisions for your business Learn more
Headquarters Switzerland
Address Lichtstrasse 35, Basel, Basel-Stadt, 4056
Website www.novartis.com
Telephone 41 613 241111
No of Employees 75,267
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange NOVN (SWF)
Revenue (2024) $56.3B 8.9% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 17.1% (2024 vs 2023)
Market Cap* $322.4B
Net Profit Margin (2024) XYZ 7.5% (2024 vs 2023)
* As of and is in US$
View Novartis AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Novartis AG premium industry data and analytics

6,800+

Clinical Trials

Determine Novartis AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2,600+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novartis AG’s relevant decision makers and contact details.

2,200+

Catalyst Calendar

Proactively evaluate Novartis AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1,400+

Marketed Drugs

Understand Novartis AG’s commercialized product portfolio to stay one step ahead of the market.

910+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

730+

Pipeline Drugs

Identify which of Novartis AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

180+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

120+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novartis AG and assess market opportunity for new entrants with patient population 8-year forecasts.

14+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novartis AG (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novartis AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Generic Medicines and Biosimilars Entresto
Pharmaceuticals: Leqvio
Cancer Vanrafia
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Novartis AG portfolio and identify potential areas for collaboration Understand Novartis AG portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2026 Contracts/Agreements In July, the company entered into an agreement to acquire Myricx Bio, a biotechnology company.
2026 Plans/Strategy In May, the company announced its plans to close its Wehr, Germany production site by the end of 2028.
2026 Plans/Strategy In April, the company announced its plans to open a new facility in Morrisville, North Carolina, the US.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Novartis AG Johnson & Johnson Eli Lilly and Co Merck & Co Inc Pfizer Inc
Headquarters Switzerland United States of America United States of America United States of America United States of America
City Basel New Brunswick Indianapolis Rahway New York City
State/Province Basel-Stadt New Jersey Indiana New Jersey New York
No. of Employees 75,267 138,200 50,605 75,000 75,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Vasant Narasimhan, MD Chief Executive Officer Senior Management 2018 50
Mukul Mehta Chief Financial Officer Senior Management 2026 53
Shreeram Aradhye, MD Chief Medical Officer; President - Global Drug Development Senior Management 2022 64
Karen L. Hale Chief Legal and Compliance Officer Senior Management 2025 58
Robert Kowalski, PhD Chief People & Organization Officer Senior Management 2021 58
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Novartis AG key executives to enhance your sales strategy Gain insight into Novartis AG key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?